HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCPC: State Legislation, ‘Fake Science,' FDA’s Sunscreen Monograph Among Top 2019 Challenges

Executive Summary

The Personal Care Products Council’s top execs identified key legislative, regulatory and public affairs challenges facing industry in 2019 during a Feb. 26 panel discussion at the group’s annual meeting in Palm Beach, Fla.

You may also be interested in...



Endocrine Disruptors, The European Green Deal And The Politicization Of EU Chemical Programs

John Chave, director-general at Cosmetics Europe, says the European Commission’s plan for targeted assessment of 28 potential endocrine-disruptors in cosmetics – despite its conclusion in late 2018 that the current cosmetics regulatory framework adequately addresses endocrine-disruptor concerns – is symptomatic of a broad trend taking hold in Europe.

Cosmetics ‘Are Not Risk-Free’; FDA Committed to Modernizing Regs – Commish Gottlieb

FDA is committed to working with Congress to update cosmetics regulations and its related authorities, as “we have not been able to expand the scope of what we’re able to do commensurate with the expansion and the scope of this industry,” Commissioner Scott Gottlieb told House appropriators Feb. 26.

California DTSC Selects Toluene In Nail Care For Potential Phase-Out

The proposal under the state’s Safer Consumer Products regulation marks the ingredient for alternative analyses and potential replacement in nail-care products. California’s Department of Toxic Substances Control cites possible dangers to salon workers in particular, including nervous system, respiratory and developmental toxicity risks.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel